TCRT Alaunos Therapeutics, Inc. Common Stock

XNAS 1.77 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TCRT $1.77 —
Key stats
$1.77
Pre-market $2.02 -5.16%
52-Week Range
$0.72 – $4.50
YTD
-46.04%
Straddle Price
$1.95
P/C Vol Ratio
0.00
Market Cap
$0.0B
Open
$2.32
Day Range
$2.01 – $2.36
Volume
537,043
Prev Close
$2.28
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.43
Cost of Equity (CAPM)12.12%
WACC12.15%
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-654.1%
Book / Price31.2% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-94166.7%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$1.63 (Market Anchor value)
SMA 20 / Bollinger Mid$1.76
Bollinger Width / SMA2012302.0% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $1.63 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
1
List Date
2005-08-24
CIK
0001107421
Next Earnings
2026-11-13
Headquarters
Fort Lauderdale, FL
Homepage
https://www.alaunos.com

Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan30.88%17.86%98.35%-13.71%-19.82%22.71%
Feb-6.99%-22.07%2.96%1.97%16.02%-1.62%
Mar-34.13%14.13%-19.02%-6.37%-13.86%-11.85%
Apr-16.70%-8.80%-28.00%13.43%-13.56%-10.73%
May5.09%-16.85%-15.50%9.82%9.20%-1.65%
Jun162.10%3.01%-37.03%79.63%-21.25%37.29%
Jul-10.00%-13.20%-43.47%-39.23%-12.96%-23.77%
Aug125.69%-70.00%-28.85%-22.26%-10.76%-1.24%
Sep-42.86%-8.34%22.90%5.70%-46.54%-13.83%
Oct-28.57%-38.08%-36.04%9.68%131.52%*7.70%
Nov-45.00%-18.27%26.47%23.25%---3.39%
Dec1.95%2.46%-26.05%8.39%---3.31%
Total-14.48%-89.87%-81.27%34.88%-42.74%-38.69%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.76
SMA 50: $1.63
SMA 200: $2.35
Current: $2.13
EMA 12: $2.31
EMA 26: $1.94
MACD: 0.3621 | Signal: 0.0822
BULLISH
ADX (14): 60.60
STRONG TREND
+DI: 35.38
−DI: 15.39

Momentum Oscillators

RSI (14): 52.78
NEUTRAL
Stoch %K: 47.92
Stoch %D: 55.75
Williams %R: -61.69

Volume & Volatility

BB Upper: $3.65
BB Lower: $-0.14
NEUTRAL
OBV: 301,416,793
Vol SMA 20: 21,474,113
Vol ROC: -84.44%
ATR: $0.54
True Range: $0.35
HV 20: 451.2%
HV 30: 386.7%
HV 60: 273.2%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Oversold RSI and MACD signal, indicating potential buy signal
  • Strong trend strength with ADX at 39.24, regime is trend
  • Beta of 1.24 indicates high risk relative to market

Primary risks:

  • High volatility, which may lead to increased price fluctuations
  • Bearish MACD signal and negative news sentiment

Investment thesis:

TCRT presents a potentially attractive buying opportunity due to its oversold technical indicators and strong trend strength. However, the high volatility and bearish MACD signal should be monitored closely.

Recent news sentiment impact:

The neutral news headlines from Benzinga did not significantly impact TCRT's stock price. The focus remains on the technical signals and market trends.

Technical Analysis

Trend Direction:

  • Short-term: Bullish (RSI oversold, MACD bearish signal)
  • Medium-term: Bullish (SMA 50 above SMA 20, ADX trend strength)
  • Long-term: Bearish (SMA 200 below current price)

Support/Resistance Levels:

  • Upper Bollinger Band: $2.02
  • Middle Bollinger Band: $1.76
  • Lower Bollinger Band: $1.49

Momentum Signals:

  • RSI: Oversold (29.09), indicating potential buy signal
  • MACD: Bearish signal (-0.10 / -0.01 / -0.09)
  • Bollinger Bands: Neutral (price within the bands)

News & Sentiment Analysis

Recent Headlines Summary:

The recent news headlines from Benzinga were neutral, not significantly impacting TCRT's stock price.

Sentiment Assessment:

Neutral sentiment prevails, with no clear buy or sell signal emerging from the news headlines.

Catalyst Identification:

No specific catalysts are identified in the recent news headlines. The focus remains on technical signals and market trends.

Risk & Volatility Assessment

Risk Interpretation:

High risk relative to market (beta 1.24)

Volatility Regime:

High volatility regime, with an average true range of $0.10

Options Market Signals:

IV rank is low (0.0%), indicating historically low volatility. The put/call volume ratio is bullish (558 calls vs 2 puts), and the market expectation is a potential move of $1.95 by expiration.

Market Context & Positioning

Sector Performance:

TCRT's sector performance is not provided, but it can be inferred that the stock is trading within its normal range relative to the broader market.

Institutional Activity:

No clear institutional activity signals are present in the data.

Correlation Analysis:

The correlation with the market (R-squared) is 0.20, indicating a relatively low correlation between TCRT and the broader market.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band: $1.49
  • Middle Bollinger Band: $1.76

Breakout/Breakdown Levels:

  • Upper Bollinger Band: $2.02 (breakout level)

Time-Sensitive Catalysts:

No specific time-sensitive catalysts are identified.

Risk Management:

Stop-loss levels should be set at the lower Bollinger Band ($1.49) or other critical price levels. Position sizing considerations should prioritize risk management and volatility control.

By considering both the technical signals and market trends, TCRT presents a potentially attractive buying opportunity. However, high volatility and bearish MACD signal require close monitoring to manage risk effectively.

Generated
News
All TCRT news →
Earnings History
1 of 3 under expected move
Avg Expected Move
28.76%
Avg Actual Move
4.94%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2022-05-16 unknown 0.83% 3.82% 4.60x Exceeded
2022-11-14 Pre-Market 0.60% 6.48% 10.80x Exceeded
2024-10-10 unknown 84.84% 4.52% 0.05x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TCRT Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $1.95
7-DTE Move: $1.95
Days to Exp: — (2025-01-17)

Options Flow

Call Volume: 558
Put Volume: 2
P/C Volume: 0.004
BULLISH
Call OI: 8,995
Put OI: 12
P/C OI: 0.001
Total OI: 9,007

ATM Options Pricing

ATM Call: $0.03
ATM Put: $1.93
Call %: 1.4%
Put %: 108.8%

Chain Summary

Chain Volume: 560
Chain OI: 9,007
Last Updated: 1/17/2025
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Jan 15 · No data
30 DTE / 10d —
— pts EXTREME
as of Jan 15 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.95Jan 17
Beta Analysis

Risk Metrics

Beta: 1.3865
Alpha: 88.12%
Correlation: 0.0824
R-Squared: 0.7%
Stock Volatility: 214.5%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own TCRT
1 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$27K
0.00%
#6126 of 6285+12.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TCRT Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 1,939,024 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

31 filers120,608 shares$302.10K value6.22% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 30,061 $97.10K 32.14% 1.55% 2025-12-31
2 BlackRock, Inc. Custodian 21,353 $48.26K 15.97% 1.10% 2026-06-30
3 Geode Capital Management, LLC Custodian 19,356 $43.75K 14.48% 1.00% 2026-06-30
4 Vanguard Fiduciary Trust Co 15,497 $35.02K 11.59% 0.80% 2026-06-30
5 Vanguard Capital Management LLC 14,063 $31.78K 10.52% 0.73% 2026-06-30
6 Citadel Advisors LLC Custodian 11,870 $26.83K 8.88% 0.61% 2026-06-30
7 OSAIC HOLDINGS, INC. Custodian 1,731 $3.91K 1.29% 0.09% 2026-06-30
8 Tower Research Capital LLC (TRC) Custodian 1,621 $3.66K 1.21% 0.08% 2026-06-30
9 Arax Advisory Partners Custodian 1,216 $2.75K 0.91% 0.06% 2026-06-30
10 UBS Group AG Custodian 992 $2.24K 0.74% 0.05% 2026-06-30
11 Morgan Stanley Custodian 836 $1.89K 0.63% 0.04% 2026-06-30
12 Vanguard Global Advisers, LLC 501 $1.13K 0.37% 0.03% 2026-06-30
13 Royal Bank of Canada Custodian 375 $1.00K 0.33% 0.02% 2026-06-30
14 CIBC Private Wealth Group LLC 300 $969 0.32% 0.02% 2025-12-31
15 Wells Fargo & Company Custodian 388 $877 0.29% 0.02% 2026-06-30
16 Steward Partners Investment Advisory, LLC 112 $253 0.08% <0.01% 2026-06-30
17 Federation des caisses Desjardins du Quebec Custodian 70 $158 0.05% <0.01% 2026-06-30
18 BOKF, NA 66 $149 0.05% <0.01% 2026-06-30
19 Axiom Investment Management LLC 46 $104 0.03% <0.01% 2026-06-30
20 Key Financial Inc 24 $54 0.02% <0.01% 2026-06-30
21 LANARK FINANCIAL, INC. 20 $45 0.01% <0.01% 2026-06-30
22 Barclays PLC Custodian 15 $34 0.01% <0.01% 2026-06-30
23 Sunbelt Securities, Inc. 10 $29 <0.01% <0.01% 2026-03-31
24 CWM, LLC Custodian 8 $23 <0.01% <0.01% 2026-03-31
25 SIGNATUREFD, LLC 23 $20 <0.01% <0.01% 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

TCRT Insider Trading (Form 4)

Latest: 2026-10-08
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-08 Robert W Postma Director Award (A) +21,829 $0.74 $16.2K EDGAR
2026-10-08 Michael Allen Jerman Director Award (A) +20,990 $0.74 $15.6K EDGAR
2026-10-08 Holger Weis CEO Award (A) +23,564 $0.74 $17.5K EDGAR
2026-10-08 Jaime Vieser Director Award (A) +22,669 $0.74 $16.9K EDGAR
2026-08-11 Holger Weis CEO Award (A) +4,363 $2.01 $8.8K EDGAR
2026-07-27 Holger Weis CEO Award (A) +4,568 $1.92 $8.8K EDGAR
2026-07-27 Michael Allen Jerman Director Award (A) +8,138 $1.92 $15.6K EDGAR
2026-07-27 Robert W Postma Director Award (A) +8,463 $1.92 $16.2K EDGAR
2026-07-27 Jaime Vieser Director Award (A) +8,789 $1.92 $16.9K EDGAR
2026-07-02 Holger Weis Chief Executive Officer Award (A) +3,880 $2.26 $8.8K EDGAR
2026-06-17 Holger Weis Chief Executive Officer Award (A) +7,761 $2.26 $17.5K EDGAR
2026-05-27 Holger Weis Chief Executive Officer Award (A) +3,700 $2.37 $8.8K EDGAR
2026-05-01 Michael Allen Jerman Director Award (A) +6,032 $2.59 $15.6K EDGAR
2026-05-01 Robert W Postma Director Award (A) +6,274 $2.59 $16.2K EDGAR
2026-05-01 Jaime Vieser Director Award (A) +6,515 $2.59 $16.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TCRT Insider Holdings

5 insiders · @ $2.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Jaime Vieser Director 83,814 $178.5K $806.5K 13 2026-10-08
2 Robert W Postma Director 80,462 $171.4K $487.5K 13 2026-10-08
3 Holger Weis CEO 49,054 $104.5K $0 12 2026-10-08
4 Michael Allen Jerman Director 44,749 $95.3K $0 6 2026-10-08
5 Ferdinand Groenewald Vice President of Finance 10,775 $23.0K $0 3 2025-08-20
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TCRT Board & Officers

As of SEC filings through Oct 15, 2026

Directors 7

Officers 2

10% owners 5

Changes in the last 10 years (60)
Oct 13, 2026Tomas Kiselak became a 10% owner
Oct 13, 2026Peter Evan Harwin became a director
Oct 13, 2026Peter Evan Harwin became a 10% owner
Oct 13, 2026Fairmount Healthcare Fund II L.P. became a director
Oct 13, 2026Fairmount Healthcare Fund II L.P. became a 10% owner
Oct 13, 2026Fairmount Healthcare Co-Invest VII L.P. became a director
Oct 13, 2026Fairmount Healthcare Co-Invest VII L.P. became a 10% owner
Oct 13, 2026Fairmount Funds Management LLC became a director
Oct 13, 2026Fairmount Funds Management LLC became a 10% owner
May 27, 2026Holger Weis no longer listed as a director in SEC filings
Jul 16, 2025The company announced the departure of Melinda Lackey as Legal & Administration in an SEC filing
Jul 15, 2025The company announced the departure of Dale Curtis Hogue Jr. as Interim CEO in an SEC filing
Jul 15, 2025Michael Allen Jerman became a director
Jul 7, 2025Holger Weis first listed as Chief Executive Officer in an SEC filing
Jul 1, 2025The company announced the departure of Dale Curtis Hogue Jr. from the board in an SEC filing
Apr 15, 2025The company announced the departure of Robert Hofmeister from the board in an SEC filing
Aug 16, 2024Melinda Lackey listed as Legal & Administration (previously Senior Vice President, Legal) in SEC filings
Feb 22, 2024Ferdinand Groenewald became VP, Finance
Feb 15, 2024The company announced the departure of Michael Wong as Vice President of Finance in an SEC filing
Jan 23, 2024Dale Curtis Hogue Jr. first listed as Interim CEO in an SEC filing
Not reported recently (23)
  • Drew Deniger · Last reported as VP, Research & Development in an SEC filing dated Mar 17, 2023
  • Abhishek K Srivastava · Last reported as Vice President, Technical Operations in an SEC filing dated Mar 17, 2023
  • Eleanor De Groot · Last reported as EVP, Operations in an SEC filing dated Apr 1, 2022
  • Raffaele Baffa · Last reported as Chief Medical Officer in an SEC filing dated May 19, 2021
  • J Kevin Buchi · Last reported as a director in an SEC filing dated May 6, 2021
  • Robert Hadfield · Last reported as General Counsel and Secretary in an SEC filing dated Mar 8, 2021
  • Heidi Hagen · Last reported as Interim CEO in an SEC filing dated Mar 8, 2021
  • Jill Buck · Last reported as EVP, GM Gene Therapy in an SEC filing dated Mar 8, 2021
  • Timothy M. Cunningham · Last reported as interim CFO in an SEC filing dated Feb 26, 2021
  • Kevin G Lafond · Last reported as SVP, Treasurer & CAO in an SEC filing dated Jan 12, 2021
  • Laurence James Neil Cooper · Last reported as Chief Executive Officer in an SEC filing dated Jan 6, 2021
  • David M Md Mauney · Last reported as President in an SEC filing dated Jan 31, 2020
  • Sath Shukla · Last reported as EVP, Chief Financial Officer in an SEC filing dated Jan 31, 2020
  • Scott Tarriff · Last reported as a director in an SEC filing dated Jan 3, 2020
  • Douglas W. Pagan · Last reported as a director in an SEC filing dated Jan 3, 2020
  • Elan Ezickson · Last reported as a director in an SEC filing dated Jan 3, 2020
  • Scott Braunstein · Last reported as a director in an SEC filing dated Jan 3, 2020
  • James Anthony Cannon · Last reported as a director in an SEC filing dated May 8, 2019
  • Wyche Fowler · Last reported as a director in an SEC filing dated Jan 3, 2018
  • Michael Weiser · Last reported as a director in an SEC filing dated Jan 3, 2018
  • Murray Brennan · Last reported as a director in an SEC filing dated Jan 3, 2018
  • Caesar J Belbel · Last reported as COO, CLO, and Secretary in an SEC filing dated Jan 3, 2018
  • Francois Lebel · Last reported as Executive Vice President R&D in an SEC filing dated Jan 3, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TCRT Proposed Insider Sales (Form 144)

Latest: 2024-12-31
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-12-31 Vieser Jaime Director 3,000 $6.5K 2024-12-31 Fidelity Brokerage Services LLC — EDGAR
2023-09-01 Boyle Kevin S. Sr. Officer 70,401 $9.5K 2023-09-01 RAYMOND JAMES & ASSOCIATES INC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
1 ETF hold TCRT
1 shown · $12.36K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VXF Vanguard Extended Market ETF Vanguard 0.00% $12,364 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.13
TTM Revenue
$3.00K
TTM Net Income
$-4.36M
TTM Op. Cash Flow
$-3.13M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-1.16M$-0.59$-1.03M
Q4 '252025-12-31$3.00K$-999.00K$-0.36$-552.00K
Q3 '252025-09-30—$-1.16M$-0.55$-844.00K
Q2 '252025-06-30—$-1.05M$-0.63$-701.00K
Q1 '252025-03-31$2.00K$-1.07M$-0.67$-772.00K
Q4 '242024-12-31$4.00K$-742.00K$-0.46$-592.00K
Q3 '242024-09-30—$-1.13M$-0.70$-781.00K
Q2 '242024-06-30$4.00K$-1.13M$-0.71$-1.68M
Q1 '242024-03-31$1.00K$-1.68M$-1.05$-1.92M
Q4 '232023-12-31$1.00K$-7.84M$-4.90$-7.38M
Q3 '232023-09-30—$-8.48M$-5.30$-6.37M
Q2 '232023-06-30$4.00K$-8.77M$-5.49$-7.00M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-15
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.21
P/S
1376.71
EV/EBITDA
—
EV/Sales
1258.71
ROE
-338.8%
ROA
-231.8%
Div Yield
0.00%
FCF Yield
-75.74%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$4.13M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
9.74K
SI % of Float
0.36%
Days to Cover
1.00
Short Vol Ratio
55.2%
Free Float
2.69M
Float %
78.3%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-10-15